SCD & gene therapy: Who is it for?

When we hear the words gene therapy, it can sound like something out of a science-fiction film; a promise to rewrite the very code of life. Yet today, gene therapy is no longer just a dream. It is here, changing lives in ways many of us never imagined. But what does it mean, and who is it really for?

Gene therapy is a treatment that goes straight to the root of certain illnesses: our genes. Genes are the body’s instructions, its blueprint. They tell our cells how to grow, how to function and how to survive. But when just one instruction carries a mistake, the body suffers.

This is what happens in Sickle Cell Disease. A single mutation changes the shape of red blood cells, twisting them into sickles that block blood vessels, trigger unbearable pain and damage vital organs. Traditional treatments, like hydroxyurea or regular blood transfusions, only manage symptoms. They cannot touch the faulty gene itself. Gene therapy, however, is different. It aims to correct the mistake at its source, giving the body a chance to produce healthy red blood cells again.

Who is it for? Right now, gene therapy is mostly for people with serious inherited illnesses caused by a single faulty gene: Sickle Cell Disease, thalassaemia, spinal muscular atrophy and even some rare forms of blindness. For people with these conditions, gene therapy offers something no other treatment has ever truly offered: the chance of freedom, the possibility of a cure.

In SCD, the process often begins with collecting a patient’s stem cells; those special cells in the bone marrow that create blood. Scientists take these cells into a laboratory and use advanced tools, sometimes even CRISPR, to repair the faulty gene.

Then the repaired cells are returned to the patient. Suddenly, the same body that once produced sickled cells can begin producing healthy ones. It is nothing short of extraordinary.

But it is not simple. Gene therapy is not a pill or a quick injection. The process is long and demanding. Patients may need chemotherapy to prepare their bodies for the new cells. That brings risks: infertility, infection and weakened immunity. And because the therapy is still new, no one yet knows exactly how long its benefits will last. For some, it has worked beautifully. For others, the results have been uncertain.

And then comes the most difficult truth: the question of access. Who can actually receive gene therapy? At the moment, only a few. The cost is staggering, often more than a million pounds for one patient. It means that access is limited to wealthy countries and specialised hospitals.

Here lies the cruel irony. SCD is most common in sub-Saharan Africa, India and parts of the Caribbean. Yet those very regions where the need is greatest are the least likely to benefit. A child born in London may one day have access to gene therapy. A child born in Lagos, Accra or Kingston may not.

So, gene therapy is both a medical revolution and a mirror. A revolution, because it proves that our DNA does not have to define our destiny. A mirror, because it reflects the inequalities of our world. It forces us to ask hard questions: Who gets to be cured? Who gets left behind? And what does that say about the value we place on human life?

Gene therapy is about science, yes, but it is also about people. It is about the child who dreams of a future without pain. The teenager who wants to finish school without endless hospital stays. The adult who longs to build a career or a family without being overshadowed by crises. It is about rewriting stories of struggle into stories of possibility.

Yet we must remain cautious. Gene therapy is not a magic wand. It cannot erase every complication of SCD or instantly heal decades of damage. But it does open a new path. A path where science, compassion and justice might finally come together to change what once felt unchangeable.

So, who is gene therapy for? It is for the pioneers, the patients who step forward into trials, brave enough to face the unknown. It is for families who have carried the grief of generations and dare to believe in something better for their children. It is for communities long ignored by the medical world, now demanding recognition and equal access.

Gene therapy is not yet for everyone. But it is for anyone who believes that hope should not depend on a postcode. That science should not be reserved for the privileged few. That a child born in Africa should have the same chance of a cure as a child born in Europe or America.

The story of gene therapy is still being written. The question is not only who it is for today, but who it must become for tomorrow. Because true progress will not be measured only by the lives it transforms in rich hospitals, but by the day it reaches every corner of the world.

Until then, gene therapy stands as both triumph and challenge. A glimpse of what medicine can achieve and a reminder of the work still to be done to make hope belong to us all.

If you would like to get in touch with me about sickle cell, do so via my email address: [email protected]. And do check out my blog: https://www.dailylivingwithsicklecell.com/.

My book on sickle cell, HOW TO LIVE WITH SICKLE CELL, and my other books are available for purchase on www.amazon.com.